FluoGuide provides strategic update and outlines development plans towards commercialization of FG001 - FluoGuide A/S
Market Notice 18/21 – FluoGuide A/S will be delisted after close of the market on February 15, 2021
History - FluoGuide A/S
Fluoguide skyder op med 34 pct. på første børsdag: "Det var vildt at se" — MedWatch
FluoGuide A/S is awarded Best IPO in 2019 by the independent IPO Guide - Fluoguide
YEAR END REPORT 2022
FluoGuide A/S - Flagging message - FluoGuide A/S
Presentations - FluoGuide A/S
Presentations - FluoGuide A/S
FluoGuide A/S is awarded Best IPO in 2019 by the independent IPO Guide - FluoGuide A/S
Board of directors - FluoGuide A/S
190401 Today the subscription period in FluoGuide commences MA
YEAR-END REPORT JANUARY – DECEMBER 2020
Presentations - FluoGuide A/S
FluoGuide (@FluoGuide) / X
FluoGuide (@FluoGuide) / X
Fluoguide flytter børs efter stigning på over 2000 pct.: "Det er starten på transformationen af selskabet" — MedWatch
FluoGuide confirms positive topline results from phase lla trial of FG001 in head & neck cancer at International Academy of Oral Oncology conference
Precision Surgery Improving Outcomes for Cancer Patients - FluoGuide A/S
Morten Albrechtsen on LinkedIn: FluoGuide receives FDA Orphan Drug Designation for FG001 in high-grade…
FluoGuide tar in nytt kapital för att förbereda fas...
FluoGuide presenterar i BioStock-studion - BioStock
History - FluoGuide A/S
Important information in English about the transfer to Nasdaq First North - FluoGuide A/S
INVITATION TO SUBSCRIBE FOR UNITS | FluoGuide
